CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy	Recruiting	Early phase 1	2026-05-12		NCT07337785

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nanjing Bioheng Biotech Co., Ltd.	10
Tongji Hospital	276

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	28